Physician profile
Brooke A Walling
NPI 1184234130
$2,046.42
in general payments reported to CMS, 2019-2025
24 companies · $338 in 2025
The $338 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $107 · 2022: $608 · 2023: $380 · 2024: $613 · 2025: $338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,331.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $448.67 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $264.72 | 2022-2025 | |
| Glaxosmithkline, LLC. | $256.59 | 2021-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Janssen Pharmaceuticals, INC | $154.56 | 2024 | Spravato |
| Astrazeneca Pharmaceuticals LP | $123.77 | 2022-2025 | Airsupra |
| Lilly USA, LLC | $103.90 | 2022-2024 | Jardiance, Zepbound |
| Pfizer INC. | $85.32 | 2023-2025 | |
| Dexcom, INC. | $72.95 | 2023 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $70.05 | 2022-2024 | Trintellix |
| Astellas Pharma US INC | $69.29 | 2022-2024 | Veozah |
| Amgen INC. | $53.17 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.40 | 2022 | |
| Insulet Corporation | $41.30 | 2021 | |
| Eisai INC. | $39.67 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $39.10 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $37.80 | 2023 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $26.54 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $23.38 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.88 | 2022 | |
| Sanofi-Aventis U.S. LLC | $17.34 | 2022 | |
| Currax Pharmaceuticals LLC | $16.74 | 2025 | Contrave, Onzetra Xsail |
| Xeris Pharmaceuticals, INC. | $13.64 | 2024 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $12.60 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $11.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Walling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.